The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …

Despite advances in treatment, cancer remains a leading cause of death worldwide.
Although treatment strategies are continually progressing, cancers have evolved many …

Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted
therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered …

Cancer Immunotherapy relies on harnessing a patient's immune system to fine-tune specific
anti-tumor responses and ultimately eradicate cancer. Among diverse therapeutic …

Immunotherapy is one of the promising strategies in the treatment of oncology. Immune
checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical …

Cancer immunotherapy has revolutionized the field of cancer treatment in recent years.
However, not all patients receiving cancer immunotherapy exhibit durable responses, and …

Cancer is a top-ranked life-threatening disease with intratumor heterogeneity. Tumor
heterogeneity is associated with metastasis, relapse, and therapy resistance. These factors …

Glioblastoma (GBM) is an obligatory lethal brain tumor with a median survival, even with the
best standard of care therapy, of less than 20 months. In light of this fact, the evaluation of …

An accumulation of previous work has established organoids as good preclinical models of
human tumors, facilitating translation from basic research to clinical practice. They are …

Adenoviruses are well characterized and thus easily modified to generate oncolytic vectors
that directly lyse tumor cells and can be" armed" with transgenes to promote lysis, antigen …